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Abstract
Background: To investigate whether the reason to discontinue the first TNF inhibitor (TNFi) affects the response to
the second TNFi in axial spondyloarthritis (axSpA).
Methods: Patients with axSpA from the Rheumatic Diseases Portuguese Register (ReumaPt), who discontinued their
first TNFi and started the second TNFi between June 2008 and May 2018, were included. Response was assessed by
the Ankylosing Spondylitis Disease Activity Score (ASDAS) clinically important improvement (ASDAS-CII), major
important improvement (ASDAS-MI), low disease activity (ASDAS-LDA), and inactive disease (ASDAS-ID). The reason
for discontinuation of the first TNFi was defined, according to ASDAS-CII as primary failure (no response ≤ 6
months), secondary failure (response ≤ 6 months but lost thereafter), adverse events, and others. The association
between the reason for discontinuation of the first TNFi and response to the second TNFi over time was assessed
in multivariable generalized equation (GEE) models.
Results: In total, 193 patients were included. The reason for discontinuation of the first TNFi did not influence the
response to the second TNFi, according to the ASDAS-CII. However, a difference was found with more stringent
outcomes, e.g., there was a higher likelihood to achieve ASDAS-ID with the second TNFi for patients discontinuing
the first TNFi due to secondary failure (OR 7.3 [95%CI 1.9; 27.7]), adverse events (OR 9.1 [2.5; 33.3]), or other reasons
(OR 7.7 [1.6; 37.9]) compared to primary failure.
Conclusion: Patients with axSpA with secondary failure to their first TNFi, compared to those with primary failure,
have a better response to the second TNFi according to stringent outcomes.
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Spondyloarthritis
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Background
Tumor necrosis factor inhibitors (TNFi) have revolu-
tionized the treatment of patients with axial spondyloar-
thritis (axSpA). Nevertheless, some patients discontinue
TNFi [1] either because of inefficacy or safety reasons.
The number of discontinuations varies across studies
but can go up to 50–60% in 2 years [2]. In such circum-
stances, the practicing clinician has to decide what to
offer as a second-line therapy, considering the available
treatment options.
For many years, TNFi were the only biological disease-
modifying drugs (bDMARD) with proved efficacy in
axSpA. More recently, secukinumab and ixekizumab, both
IL-17 inhibitors (IL-17i), have demonstrated efficacy in
phase 3 randomized controlled trials (RCTs) [3–5], both in
TNFi-naive and TNFi-experienced patients with radio-
graphic axial spondyloarthritis (r-axSpA). Part of these data
already translated into a change in the 2016 update of the
Assessment of SpondyloArthritis International Society–
European League Against Rheumatism (ASAS-EULAR)
management recommendations for axSpA [6] which pre-
scribes switching to another TNFi or an IL-17i in case of
failure of the first TNFi.
In 2019, the American College of Rheumatology/Spon-
dylitis Association of America/Spondyloarthritis Re-
search and Treatment Network (ACR/SAA/SPARTAN)
2019 update on the treatment recommendations for
axSpA [7] prioritized an IL-17i over a second TNFi in
patients with primary non-response to the first TNFi
and a second TNFi over an IL-17i for those with second-
ary non-response (after 6 months). This recommenda-
tion reflects the long-lasting hypothesis that the reason
for discontinuing the first TNFi affects the response to
the second TNFi. However, evidence to support such
hypothesis is still scarce. In the absence of RCTs to
address this clinically relevant issue, clinicians have
relied on data stemming from observational studies
yielding conflicting results, thus precluding definitive
conclusions [2, 8–12].
The aims of this study were twofold: to compare the
efficacy of TNFi as the first-line and second-line therapy
and to assess whether the reason for discontinuation of
the first TNFi affects the response to the second TNFi in
patients with axSpA.
Methods
Patients and study design
In this prospective multicenter cohort study, adult
patients with axSpA, according to their treating rheuma-
tologists, registered in Reuma.pt (Rheumatic Diseases
Portuguese Register) who discontinued their first TNFi
(for any reason) and started a second TNFi between June
2008 and May 2018, were included. Patients were re-
quired to have complete data on Ankylosing Spondylitis
Disease Activity Score (ASDAS) at baseline and 3 and 6
months after starting the first TNFi. Patients were
assessed at baseline, 3 months, 6 months, and then every
6 months, up to 10 years of follow-up. Data was collected
by the treating rheumatologist and stored centrally in
the Reuma.pt online database. Reuma.pt is a nationwide
clinical register, established and managed by the Portuguese
Society of Rheumatology, in which data from patients with
various rheumatic diseases is recorded. Since 2008, patients
have been included in the register, with regular information
on their visits to the rheumatologist. First patients with in-
flammatory arthritis including rheumatoid arthritis, axSpA,
psoriatic arthritis, and juvenile idiopathic arthritis on bio-
logical treatment were included, and later, the register was
expanded to other treatments and also to other diseases. A
detailed report of the design of Reuma.pt and data manage-
ment procedures has been published elsewhere [13].
For the current study, a dedicated team of researchers
from each participating center was assigned to compare
information on a core set of variables between the
central database and the medical records, in order to
complete missing information whenever possible.
Reuma.pt has been approved by the ethics committees
of the participating hospitals and complies with the
Declaration of Helsinki. This specific study has been
approved by the ethics committee of the NOVA Medical
School, Lisbon, Portugal. Patients have signed a written
informed consent before inclusion.
Outcomes
The main outcome was the ASDAS clinically important
improvement (ASDAS-CII), defined as a decrease from
baseline of ≥ 1.1 units of the ASDAS score. Secondary
outcomes were as follows: ASDAS major improvement
(ASDAS-MI), defined as a decrease from baseline of ≥
2.0 units; ASDAS low disease activity (ASDAS-LDA), i.e.,
an ASDAS < 2.1 [14]; ASDAS inactive disease (ASDAS-
ID), i.e., ASDAS < 1.3; and the Bath Ankylosing Spondyl-
itis Disease Activity Index 50 (BASDAI50), defined as
50% improvement compared to baseline.
Reason to discontinue TNFi
The reason for discontinuation of the first TNFi was
defined as follows: (i) primary failure, if ASDAS-CII was
not achieved at 3 or 6 months; (ii) Secondary failure, if
ASDAS-CII was achieved at 3 or 6 months but lost in ≥
1 subsequent visit; (iii) adverse event; and (iv) others
(e.g., pregnancy, surgery). Primary and secondary failure
were defined a posteriori by computing the response
according to the ASDAS-CII in patients with reported
discontinuation due to the lack of efficacy by the treating
rheumatologist. For patients with ≥ 1 reason for discon-
tinuation recorded by their treating rheumatologist, the
“main” reason was defined in a case-by-case decision
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basis. For instance, if a patient experienced a severe
adverse event by the time of discontinuation, this was
selected as the main reason even if ASDAS-CII had not
been achieved.
An alternative definition of secondary failure to the
first TNFi was used in a sensitivity analysis. A patient
was considered to have a secondary failure if he/she
experienced a flare (ASAS definition, 0.9 point increase
in ASDAS between two consecutive time points) [15],
comparing to the immediately preceding visit (or to 2
previous visits, if the preceding was missing for ASDAS),
at least once, after achieving ASDAS-CII at 3 or 6
months.
Statistical analysis
Baseline characteristics were described, at the start of
the second TNFi, for the entire population and com-
pared according to the reason for discontinuation of the
first TNFi using analysis of variance (ANOVA) for con-
tinuous variables and the χ2 test for categorical variables.
The proportion of patients meeting the efficacy out-
comes, at 3 and 6months, was assessed both for the first
and second TNFi (in patients with complete data for
each outcome and per time point), adjusting for poten-
tial confounders selected a priori on clinical grounds
(age, gender, and C-reactive protein (CRP) levels at base-
line) in logistic regression models.
The association between the reason for discontinu-
ation of the first TNFi and response to the second TNFi
during up to 10 years of follow-up was tested in bino-
mial generalized estimating equation (GEE) models, to
take into account the within-patient correlation across
repeated measures of the outcome over time. All models
were adjusted for age, gender, and CRP, the latter
modeled as time-varying. A sensitivity analysis was
conducted in the same way. p values lower than 0.05
were considered significant. Data analysis was performed
using Stata version 14.0.
Results
Patient characteristics
In total, 346 patients with axSpA registered in Reuma.pt
by the time of database lock (May 2018) had discontin-
ued the first TNFi and started the second TNFi; out of
these, 193 had available data for ASDAS at baseline, 3
and 6months for the first TNFi, and were therefore
included. Patients had a mean age of 45 years, 53% were
male, 61% were HLA-B27-positive, had a mean follow-
up of 1.5 years (range 3 months to 10 years), and 149
(88%) had radiographic axSpA. Patients eligible for the
study were largely similar to those excluded (Online
Supplementary Table S1).
Patients’ characteristics according to the reason for
discontinuation of the first TNFi
Most baseline characteristics were similar across the
reason for discontinuation of the first TNFi, includ-
ing co-medication (non-steroidal anti-inflammatory
drugs (NSAIDs), glucocorticoids, and conventional
synthesis disease-modifying drugs (csDMARD))
(Online Supplementary Table S2). The proportion of
male patients was higher among patients who dis-
continued their first TNFi due to secondary failure
(60%) and adverse events (59%) than among patients
with primary failure (25%) and other reasons for
discontinuation (41%).
Only 31% of patients with primary failure had an ele-
vated CRP (≥ 0.5 mg/dL) at baseline. This percentage
was higher for secondary failure, adverse events, and
other reasons, 70%, 55%, and 53%, respectively.
Comparison of response between the first and second TNFi
In total, 96 patients had data for ASDAS for the first
and second TNFi at baseline and 3 months and 79 at
baseline and 6 months. The adjusted response rate to
the second TNFi was lower compared to the response
to the first TNFi (Table 1). For some outcomes, the
difference was large, e.g., ASDAS-CII at 3 months
(41% vs 51%) and 6 months (35% vs 56%) and ASDA
S-MII at 3 months (13% vs 33%) and 6 months (22%
vs 32%).
Table 1 Efficacy of the first and second TNFi (adjusted models)
1st TNF % (95% CI) 2nd TNF % (95% CI)
Outcome at 3M defined (n = 96*)
ASDAS CII 51 (42; 60) 41 (31; 50)
BASDAI50 45 (36; 54) 39 (29; 48)
ASDAS MII 33 (25; 42) 13 (6; 19)
ASDAS LDA 42 (32; 51) 26 (18; 35)
ASDAS inactive 19 (12; 26) 16 (9; 22)
Outcome at 6M defined (n = 79*)
ASDAS CII 56 (46; 66) 35 (26; 45)
BASDAI50 46 (35; 56) 33 (23; 43)
ASDAS MII 32 (22; 41) 22 (13; 30)
ASDAS LDA 41 (30; 51) 29 (19; 39)
ASDAS inactive 11 (5; 18) 15 (8; 22)
Percentages and 95% CI are derived from logistic regression models adjusted
for age, gender, and CRP at baseline
ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing
Spondylitis Activity Index, LDA low disease activity, ID inactive disease, CII
clinically important improvement, MII major important improvement, BASDAI50
Bath Ankylosing Spondylitis Disease Activity Index 50, TNFi tumor necrosis
factor inhibitor, M months
*96 patients had ASDAS and BASDAI outcomes available at baseline and 3
months for both TNFi; 79 patients had ASDAS and BASDAI outcomes available
at baseline and 6months for both TNFi
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Association between reason for discontinuation of the
first TNFi and efficacy of the second TNFi
There was no association between the reason to discon-
tinue the first TNFi and response to the second TNFi as
defined by ASDAS-CII. Such association could be found
with the most stringent outcomes, namely ASDAS-MI
and ASDAS-ID (Table 2). For instance, compared to pa-
tients who discontinued their first TNFi due to primary
failure, patients were more likely to achieve ASDAS-ID
with the second TNFi if they discontinued their first
TNFi due to secondary failure (OR 7.3 [95% CI 1.9;
27.7]), adverse events (OR 9.1 [2.5; 33.3]), or other
reasons (OR 7.7 [1.6; 37.9]).
When considering the alternative definition of second-
ary failure (i.e., according to ASAS Flare), results were
mostly similar. However, patients who discontinued their
first TNFi due to secondary failure were also more likely
to achieve ASDAS-CII with the second TNFi (OR 3.0
[95%CI 1.1; 8.5]) compared to those who had primary fail-
ure to their first TNFi (Online Supplementary Table S3).
Discussion
In this prospective observational cohort study, we have
compared the response to a second TNFi according to
the reason for discontinuation of the first TNFi in
patients with axSpA using longitudinal data. Response
was better for patients discontinuing the first TNFi due
to secondary failure compared to those with primary
failure. These results can help the practicing clinician to
decide on which drug, or drug class, to use as a second-
line therapy in daily practice in patients with axSpA.
We found a lower response to the second TNFi com-
pared to the first TNFi. In a Finnish cohort study with
543 patients, the BASDAI50 response after 6 months
was achieved by 52% and 25% of the patients with their
first and second TNFi treatments, respectively [12].
Retention of the second TNFi was shorter than of the
first TNFi. In a French study with 244 patients (101
under the first TNFi and 143 on their second TNFi), the
drug survival for the first and second TNFi was 22 and
15months, respectively (p < 0.01), regardless of the
individual drug [16]. Concerning ASDAS outcomes, as
observed in our study, in a Swiss study, ASDAS-ESR in-
active disease state was reached by 4% of patients after
previous primary failure against the 22% after secondary
failure [2].
Compared to patients with primary failure, those with
secondary failure to the first TNFi had a better response
to the second TNFi, but only for the most stringent out-
comes (ASDAS-MI and ASDAS-ID). This may explain
the previous negative results. Studies in which the subtle
association between the reason for discontinuation of
the first TNFi and efficacy of the second TNFi was not
found using BASDAI [9–11], or ASAS40 as efficacy
outcomes [9], which are far less strict than ASDAS-ID.
Differences in the population and also in the methods
used to define primary and secondary failure may also
contribute to explain the differences across studies. In
our study, patients with a primary failure to the first
TNFi had, at baseline of the second TNFi, lower levels
of CRP and were also most likely female, which are
known to associate with worse response to TNFi treat-
ment [17, 18]. However, a worse response was still seen
despite adjustment for these characteristics.
Our study is not without limitations. First, residual
confounding can still explain the differences found
between patients discontinuing the first TNFi due to
primary and secondary failure. The number of con-
founders that we could adjust for was also limited by
the small sample size. However, residual confounding
is an inherent problem in observational research, and
arguably, we have adjusted for the most relevant con-
founders. Secondly, we could not compare the efficacy
of starting a second TNFi or an IL-17i, after failing
the first TNFi due to small numbers of patients
treated with IL-17i. Additionally, no information was
available on non-pharmacological interventions, which
are the first line in axSpA. Our data suggest that it
could be better to choose a drug with a mechanism
of action other than TNFi in case of primary failure
to a TNFi, and future studies should give resolution
whether that is the case for IL-17i.




Outcome for the second TNFi OR (95% CI)
ASDAS-CII (n = 135) ASDAS-MII (n = 135) ASDAS-LDA (n = 166) ASDAS-ID (n = 166) BASDAI50 (n = 147)
(Ref. primary failure)
-Secondary failure 1.9 (0.7; 4.8) 4.8 (1.3; 18.2) 1.2 (0.6; 2.4) 7.3 (1.9; 27.7) 1.4 (0.6; 3.0)
-Adverse events 1.5 (0.6; 3.5) 2.4 (0.6; 9.6) 0.9 (0.5; 1.7) 9.1 (2.5; 33.3) 1.1 (0.5; 2.3)
-Others 1.0 (0.3; 3.8) 1.7 (0.1; 19.4) 1.0 (0.4; 2.4) 7.7 (1.6; 37.9) 0.5 (0.1; 1.7)
ASDAS Ankylosing Spondylitis Disease Activity Score, LDA low disease activity, ID inactive disease, CII clinically important improvement, MII major important
improvement, BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50, N number
*Generalized estimated equation (GEE) models with the reason for discontinuation of the first tumor necrosis factor inhibitor (TNFi) as a predictor (reference
category: primary failure); all models adjusted for age, gender, and C-reactive protein. Models include all visits during follow-up of up to 10 years. Odds ratios (OR)
in bold are statistically significant (p < 0.05)
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Conclusions
In summary, on average, response to a second TNFi is
worse than the response to a first TNFi, especially
among patients that never responded in the first place to
this class of drugs.
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